



CMS Statement on Proposed Stacking of Discounts for Determining Best Price under the Medicaid Drug Rebate Program

- On May 15, 2024, the Centers for Medicare and Medicaid Services (CMS) released a statement regarding its May 2023 proposed rule titled Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program (Proposed Rule).
- Best Price means the lowest price available to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity during the rebate period for a single source drug or innovator multiple source drug. In the Proposed Rule, CMS proposed that discounts, rebates, or other arrangements must be “stacked” in a single transaction to determine the Best Price for a drug.
- In its statement, CMS noted that it will not be finalizing this proposal regarding stacking but will continue finalizing other provisions in the Proposed Rule.

More on This Topic:

- [Statement](#)
- [Proposed Rule](#)

For questions, please reach out to [Vicky Jucelin](#).

AMCP | 675 North Washington Street, Suite 220 | Alexandria, VA, 22314

[Manage Preferences](#)

